Followers | 72 |
Posts | 4259 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Thursday, January 11, 2024 10:41:26 PM
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023250298&_cid=P21-LQSR22-38874-2
Abstract
(EN) A composition of a compound represented generically by FIGURE 1A for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIGURE 1A to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating an individual, by administering a pharmaceutically effective amount of a compound of FIGURE 1A to the individual and treating the individual.
(FR) L'invention concerne une composition d'un composé représenté de manière générale par la FIGURE 1A destinée à être utilisée dans une thérapie assistée par psychotrope. L'invention concerne également une méthode de modification de la neurotransmission, par administration d'une dose pharmaceutiquement efficace d'un composé de la FIGURE 1A à un mammifère, qui interagit avec les récepteurs 5-HT2A de la sérotonine chez le mammifère, et en particulier chez les êtres humains, et induit des effets psychoactifs. L'invention concerne en outre une méthode de traitement d'un individu, par administration d'une dose pharmaceutiquement efficace d'un composé de la FIGURE 1A à l'individu, ainsi que le traitement de l'individu.
Publication Number
WO/2023/250298
Publication Date
28.12.2023
International Application No.
PCT/US2023/068668
International Filing Date
19.06.2023
IPC
A61K 31/48 2006.1 C07D 457/06 2006.1
Applicants
MIND MEDICINE, INC. [US]/[US]
Inventors
TRACHSEL, Daniel
LIECHTI, Matthias Emanuel
LUSTENBERGER, Felix
Agents
KOHN, Kenneth I.
Priority Data
63/353,673 20.06.2022 US
Publication Language
English (en)
Filing Language
English (en)
Designated States
View all
Title
(EN) LYSERGIC ACID DERIVATIVES WITH MODIFIED LSD-LIKE ACTION
(FR) DÉRIVÉS D'ACIDE LYSERGIQUE AYANT UNE ACTION DE TYPE LSD MODIFIÉE
front page image
Recent MNMD News
- MindMed to be Included in Russell 2000® and Russell 3000® Indexes • Business Wire • 06/28/2024 11:00:00 AM
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • Business Wire • 06/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:10 PM
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:10 PM
- MindMed to Participate in June Conferences • Business Wire • 05/28/2024 11:00:00 AM
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:12 PM
- MindMed Reports First Quarter 2024 Financial Results and Business Updates • Business Wire • 05/08/2024 08:01:00 PM
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM